Literature DB >> 23652066

Intestinal microcirculatory dysfunction and neonatal necrotizing enterocolitis.

Hong-yi Zhang1, Fang Wang, Jie-xiong Feng.   

Abstract

OBJECTIVE: Based on the observation that coagulation necrosis occurs in the majority of neonatal necrotizing enterocolitis (NEC) patients, it is clear that intestinal ischemia is a contributing factor to the pathogenesis of NEC. However, the published studies regarding the role of intestinal ischemia in NEC are controversial. The aim of this paper is to review the current studies regarding intestinal microcirculatory dysfunction and NEC, and try to elucidate the exact role of intestinal microcirculatory dysfunction in NEC. DATA SOURCES: The studies cited in this review were mainly obtained from articles listed in Medline and PubMed. The search terms used were "intestinal microcirculatory dysfunction" and "neonatal necrotizing enterocolitis". STUDY SELECTION: Mainly original milestone articles and critical reviews written by major pioneer investigators in the field were selected.
RESULTS: Immature regulatory control of mesentery circulation makes the neonatal intestinal microvasculature vulnerable. When neonates are subjected to stress, endothelial cell dysfunction occurs and results in vasoconstriction of arterioles, inflammatory cell infiltration and activation in venules, and endothelial barrier disruption in capillaries. The compromised vasculature increases circulation resistance and therefore decreases intestinal perfusion, and may eventually progress to intestinal necrosis.
CONCLUSION: Intestinal ischemia plays an important role through the whole course of NEC. New therapeutic agents targeting intestinal ischemia, like HB-EGF, are promising therapeutic agents for the treatment of NEC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23652066

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  7 in total

1.  Feasibility of real-time intestinal bloodstream evaluation using probe-based confocal laser endomicroscopy in a porcine intestinal ischemia model.

Authors:  Tsuyoshi Takahashi; Rie Nakatsuka; Hisashi Hara; Shigeyoshi Higashi; Kouji Tanaka; Yasuhiro Miyazaki; Tomoki Makino; Yukinori Kurokawa; Makoto Yamasaki; Shuji Takiguchi; Masaki Mori; Yuichiro Doki; Kiyokazu Nakajima
Journal:  Surg Endosc       Date:  2017-10-24       Impact factor: 4.584

2.  Dithizone-induced Paneth cell disruption significantly decreases intestinal perfusion in the murine small intestine.

Authors:  Jennifer N Berger; Huyiu Gong; Misty Good; Steven J McElroy
Journal:  J Pediatr Surg       Date:  2019-02-23       Impact factor: 2.545

3.  Recombinant human soluble thrombomodulin reduces the severity and incidence of necrotizing enterocolitis in a newborn rat model.

Authors:  Bo Li; Ryuta Saka; Yuichi Takama; Takehisa Ueno; Yuko Tazuke; Hiroomi Okuyama
Journal:  Surg Today       Date:  2019-06-12       Impact factor: 2.549

4.  [Changes in C-reactive protein and procalcitonin levels in neonates with necrotizing enterocolitis and their clinical significance].

Authors:  Li Wang; Shen-Wang Ni; Ke-Ran Zhu; Deng-Yu Zhou; Yang Wang; Li-Li Wang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2018-10

Review 5.  Update in pathogenesis and prospective in treatment of necrotizing enterocolitis.

Authors:  Gianluca Terrin; Antonella Scipione; Mario De Curtis
Journal:  Biomed Res Int       Date:  2014-07-17       Impact factor: 3.411

6.  Application of coagulation parameters at the time of necrotizing enterocolitis diagnosis in surgical intervention and prognosis.

Authors:  Wei Feng; Jinping Hou; Xiaohong Die; Jing Sun; Zhenhua Guo; Wei Liu; Yi Wang
Journal:  BMC Pediatr       Date:  2022-05-10       Impact factor: 2.567

7.  Extended-spectrum beta-lactamase (ESBL) producing Enterobacterales in stool surveillance cultures of preterm infants are no risk factor for necrotizing enterocolitis: a retrospective case-control study over 12 years.

Authors:  Martin Eberhart; Andrea Grisold; Michela Lavorato; Elisabeth Resch; Andreas Trobisch; Bernhard Resch
Journal:  Infection       Date:  2020-05-27       Impact factor: 3.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.